KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Work In Process: 2019-2025

Historic Work In Process for Ionis Pharmaceuticals (IONS) over the last 5 years, with Mar 2025 value amounting to $8.7 million.

  • Ionis Pharmaceuticals' Work In Process rose 44.84% to $8.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 44.84%. This contributed to the annual value of $6.7 million for FY2024, which is 21.95% up from last year.
  • As of Q1 2025, Ionis Pharmaceuticals' Work In Process stood at $8.7 million, which was up 30.92% from $6.7 million recorded in Q4 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Work In Process peaked at $8.7 million during Q1 2025, and registered a low of $954,000 during Q2 2021.
  • For the 3-year period, Ionis Pharmaceuticals' Work In Process averaged around $4.9 million, with its median value being $5.5 million (2023).
  • In the last 5 years, Ionis Pharmaceuticals' Work In Process tumbled by 72.52% in 2021 and then skyrocketed by 311.64% in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' Work In Process (Quarterly) stood at $5.8 million in 2021, then tumbled by 63.45% to $2.1 million in 2022, then spiked by 159.70% to $5.5 million in 2023, then climbed by 21.95% to $6.7 million in 2024, then spiked by 44.84% to $8.7 million in 2025.
  • Its Work In Process was $8.7 million in Q1 2025, compared to $6.7 million in Q4 2024 and $6.7 million in Q3 2024.